KINDLY ROTATE YOUR DEVICE TO ACCESS THE WEBSITE

FEDO PHARMA

Specialized Medicines. Strategic Focus. tailored for neurological and digestive care.

Fedo Pharma was acquired by Biotech Pharma in 2022 as part of a strategic move to strengthen the company’s presence in the central nervous system (CNS) and gastrointestinal (GIT) segments. The acquisition deepened Biotech Pharma’s portfolio, adding a robust pipeline of 20+ targeted pharmaceutical products. Fedo Pharma continues to operate with a focus on clinical relevance and market demand, further enhancing the group’s value proposition in key specialty areas.

ABOUT FEDO PHARMA

Driving Production Excellence

Fedo Pharma drives production efficiency and quality across 20+ developing products. By leveraging the group’s commercial and distribution strengths, Fedo Pharma focuses on scalable, high-quality manufacturing to support accessible, clinically relevant treatments for Egypt and beyond.

Pharmaceutical Products in Development
0 +
Toll Manufacturing Partners
0 +
SQM of Production Space
0 +

TRUSTED, CERTIFIED, COMPLIANT

A Trusted Name in Pharmaceutical Production

Fedo Pharma operates in full alignment with international pharmaceutical standards, ensuring all licensed products meet Egypt’s Ministry of Health regulations and global compliance frameworks. Our infrastructure and operations are built on certified quality systems that reflect our long-standing commitment to safety, transparency, and trust.

Elevating Specialized Care arrow

Dedicated to advancing therapeutic care by focusing expertise and resources on the central nervous system and gastrointestinal segments—addressing some of the most urgent and underserved needs in modern healthcare.

Leading in Therapeutics arrow

Aiming to be recognized as a driving force in local and regional manufacturing of CNS and GIT therapies, with a commitment to delivering consistent, high-quality pharmaceutical solutions that enhance patients’ quality of life and support healthier futures.

FEDO PHARMA

Fedo Pharma was acquired by Biotech Pharma in 2022, adding 20+ targeted CNS and GIT products to the group’s portfolio. Fedo Pharma continues to focus on clinical relevance and market demand, strengthening the group’s specialty offerings.

OUR ROLE

Fedo Pharma drives production efficiency and quality across 20+ developing products. By leveraging the group’s commercial and distribution strengths, Fedo Pharma focuses on scalable, high-quality manufacturing to support accessible, clinically relevant treatments for Egypt and beyond.

Pharmaceutical Products in Development
0 +
Toll Manufacturing
Partners
0 +
SQM of
Production Space
0 +

CNS & GIT Manufacturing

Specialized manufacturing focused on therapies for the central nervous system and gastrointestinal tract.

End-to-End Manufacturing

End-to-end capabilities spanning raw material processing, formulation, and finished dosage forms.

Integrated Quality Supply

Supply chain systems designed for consistency, regulatory compliance, and scalable growth.

TRUSTED ACCESS

Fedo Pharma operates in full alignment with international pharmaceutical standards, ensuring all licensed products meet Egypt’s Ministry of Health regulations and global compliance frameworks. Our infrastructure and operations are built on certified quality systems that reflect our long-standing commitment to safety, transparency, and trust.

TRUSTED, CERTIFIED, COMPLIANT

Expanding
Treatment Access arrow

Guided by a commitment to make advanced, specialty pharmaceuticals more accessible, supporting healthier communities through research, manufacturing excellence, and collaboration.

Advancing Specialized Care arrow

Dedicated to therapies that address complex neurological and digestive health needs, with a focus on quality, innovation, and impact.

Kindly rotate your device to view the website.

NAVIGATION MENU

HOME

ABOUT US

CAREERS

FIND US

GET IN TOUCH